Wenxin Hu

This study identifies METTL1 gene dosage and catalytic activity as therapeutic targets in pediatric cancers, showing that inhibiting METTL1 synergizes with BCL-xL inhibitors.

This study shows that Cas13 forms phase-separated RNA condensates to enhance target RNA accessibility and cleavage efficiency in both bacterial and mammalian cells.

This study shows that target RNA abundance controls collateral activity of RfxCas13d in human cells and zebrafish embryos, with high abundance causing widespread degradation and toxicity.

This paper introduces CRISPR-PspCas13b as a method to systematically silence oncogenic fusion transcripts, showing effectiveness against drug-resistant cancer drivers.

This paper develops CRISPR-Cas13 crRNAs that selectively silence oncogenic SNV transcripts with single-base precision by exploiting mismatch intolerance in target-spacer interactions.

This study designs CRISPR-Cas13b crRNAs with single-base precision to silence oncogenic gene fusions, enhancing targeting efficacy and selectivity.